Investors in Clovis Oncology (NASDAQ:CLVS) received some welcome good news when the company announced that its EGFR blocker CO-1686 received FDA's coveted breakthrough designation. This gives companies a speedier FDA review and easier access to regulators as they work to get individual drugs approved. CO-1686 targets a subset of non-small cell lung cancer patients -- a subset with no approved treatments thus far, according to Clovis.
While the news was good, it's important for investors not to overreach -- this is a drug still in pretty early clinical trials, as Clovis is currently beginning enrollment in two phase 2 expansion studies, with a New Drug Application (NDA) hopefully in the offing by mid-2015.
In the video below, from Tuesday's Market Checkup, The Motley Fool's health care-focused investing show, health care analysts Michael Douglass and David Williamson discuss this news and what it means for Clovis investors.
Will this stock be your next multi-bagger?
Give me five minutes and I'll show how you could own the best stock for 2014. Every year, The Motley Fool's chief investment officer hand-picks 1 stock with outstanding potential. But it's not just any run-of-the-mill company. It's a stock perfectly positioned to cash in on one of the upcoming year's most lucrative trends. Last year his pick skyrocketed 134%. And previous top picks have gained upwards of 908%, 1,252% and 1,303% over the subsequent years! Believe me, you don't want to miss what could be his biggest winner yet! Just click here to download your free copy of "The Motley Fool's Top Stock for 2014" today.
David Williamson has no position in any stocks mentioned. Michael Douglass has no position in any stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.